ClinicalTrials.gg
CompletedNCT03459222Updated Apr 6, 2026Results posted

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

A Phase 1/2 interventional study of Relatlimab and Nivolumab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
229
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

02

Conditions studied

  • Advanced Cancer

Keywords

  • Immunotherapy
  • Relatlimab
  • Nivolumab
  • Ipilimumab
  • BMS-986205
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic confirmation of select incurable solid that are advanced ( and/or unresectable), with per v1.1
  • Available tumor tissue for biomarker analysis
  • Performance Status (ECOG) status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Known or suspected central nervous system (CNS) or with the CNS as the only site of active disease
  • History of interstitial lung disease / pneumonitis
  • Prior active within the previous 2 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer
  • Encephalitis, meningitis, or uncontrolled seizures in the year prior to

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    Arm A

    Relatlimab + Nivolumab + BMS-986205

    Biological: Relatlimab · Biological: Nivolumab · Drug: BMS-986205

  • Experimental
    Arm B

    Relatlimab + Nivolumab + Ipilimumab

    Biological: Relatlimab · Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • BiologicalRelatlimab

    Specified dose on specified days

    Also known as: BMS-986016

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • Specified dose on specified days

    Also known as: Linrodostat

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: Yervoy, BMS-734016

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 3/Grade 4 Laboratory Test Results

    Laboratory test results are graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. Grade 3 = Severe or medically significant but not immediately life-threatening. Grade 4 = Life-threatening or disabling.

    Time frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)

  2. Number of Participants With Adverse Events and Deaths

    Adverse events are any unfavorable or unintended signs, symptoms, or diseases occurring in study participants during a clinical trial, regardless of whether they are related to the intervention. They include all-cause mortality, serious adverse events, and other events exceeding a set frequency threshold. Serious adverse events are a subset that result in significant outcomes such as death, life-threatening conditions, hospitalization or its prolongation, persistent or significant disability/incapacity, or other medically important conditions.

    Time frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)

  3. Number of Participants With Dose Limiting Toxicities

    Dose-Limiting Toxicities (DLTs) are treatment-related adverse events occurring during the first cycle (typically Days 1-28) that meet predefined severity criteria per NCI CTCAE v4.03. Hematologic DLTs include Grade 4 neutropenia \>5 days, Grade 3 neutropenia with fever, Grade 4 thrombocytopenia or Grade 3 with bleeding, and Grade 4 anemia. Non-hematologic DLTs include any toxicity ≥Grade 3 (except alopecia or controlled nausea) or treatment interruption ≥2 weeks due to adverse events.

    Time frame: From first dose (Day 1) and up to 42 days post first dose

  4. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is the percentage of participants whose best overall response is Complete Response (CR) or Partial Response (PR) per RECIST v1.1. CR is the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. ORR is calculated as: (Number of participants with CR or PR ÷ Total participants) × 100. Confidence intervals are typically estimated using the Clopper-Pearson method.

    Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)

  5. Disease Control Rate (DCR)

    Disease Control Rate (DCR) is the percentage of participants whose Best Overall Response (BOR) is Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST v1.1. CR is the disappearance of all target lesions and reduction of any pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum diameters while on study. DCR is calculated as: (Number of participants with CR, PR, or SD ÷ Total participants) × 100.

    Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)

  6. Duration of Response (DoR)

    Duration of Response (mDOR) is the median time from the first documented occurrence of Complete Response (CR) or Partial Response (PR) until disease progression or death, assessed per RECIST v1.1. CR is the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. Progression is defined as at least a 20% increase in the sum of diameters of target lesions or appearance of new lesions.

    Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progression-Free Survival (PFS) is the time from randomization or treatment start until the first documented disease progression or death from any cause, whichever occurs first, assessed per RECIST v1.1. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions (minimum 5 mm absolute increase) or appearance of new lesions. Participants without progression or death are censored at the date of last adequate tumor assessment. PFS is typically analyzed using Kaplan-Meier estimates and reported in months.

    Time frame: From the date of first dose (Day 1) to up to the date of the first documented disease progression or death (up to approximately 80 months)

  2. Progression Free Survival Rate at 6 and 12 Months

    Progression-Free Survival Rate (PFSR) is the percentage of participants who remain alive without disease progression, assessed per RECIST v1.1. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions (minimum 5 mm absolute increase) or appearance of new lesions. Participants without progression or death by the time point are considered event-free

    Time frame: Month 6 and 12

07

Results

Posted Apr 6, 2026

Participant flow

Participant flow — Overall Study
Milestone1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
Started337645546546
Completed00000302
Not completed337645516544
Withdrew: Participant request to discontinue study treatment00000210
Withdrew: Participant withdrew consent00000020
Withdrew: Death00002100
Withdrew: Adverse event unrelated to study drug00004082
Withdrew: Disease recurrence00001000
Withdrew: Other reasons01200422
Withdrew: Disease progression223630253213
Withdrew: Study drug toxicity00208161823
Withdrew: Maximum clinical benefit10000324

Outcome measures

PrimaryNumber of Participants With Grade 3/Grade 4 Laboratory Test Results

Laboratory test results are graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. Grade 3 = Severe or medically significant but not immediately life-threatening. Grade 4 = Life-threatening or disabling.

Time frame:
From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3/Grade 4 Laboratory Test Results
Participants1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
Hemoglobin Grade 300003101
Lymphocytes Grade 300109612
Lymphocytes Grade 400000020
Absolute Neutrophil Count Grade 300001010
Aspartate Aminotransferase Grade 310004734
Aspartate Aminotransferase Grade 400204300
Alanine Aminotransferase Grade 3101061437
Alanine Aminotransferase Grade 400103500
Bilirubin Grade 300100101
Creatinine Grade 300000010
Hyponatremia Grade 300001231
Hyperkalemia Grade 300000111
Hyperkalemia Grade 400000100
Hypokalemia Grade 300002130
Hypokalemia Grade 400001000
Hypercalcemia Grade 300011000
Hypocalcemia Grade 400000001
Hypermagnesemia Grade 300000001
Hypoglycemia Grade 400000100
PrimaryNumber of Participants With Adverse Events and Deaths

Adverse events are any unfavorable or unintended signs, symptoms, or diseases occurring in study participants during a clinical trial, regardless of whether they are related to the intervention. They include all-cause mortality, serious adverse events, and other events exceeding a set frequency threshold. Serious adverse events are a subset that result in significant outcomes such as death, life-threatening conditions, hospitalization or its prolongation, persistent or significant disability/incapacity, or other medically important conditions.

Time frame:
From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Deaths
Participants1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
Treatment Related Adverse Events337644546546
Serious Adverse Events116429213827
Adverse Events Leading to Discontinuation102015192322
Deaths00205274
PrimaryNumber of Participants With Dose Limiting Toxicities

Dose-Limiting Toxicities (DLTs) are treatment-related adverse events occurring during the first cycle (typically Days 1-28) that meet predefined severity criteria per NCI CTCAE v4.03. Hematologic DLTs include Grade 4 neutropenia \>5 days, Grade 3 neutropenia with fever, Grade 4 thrombocytopenia or Grade 3 with bleeding, and Grade 4 anemia. Non-hematologic DLTs include any toxicity ≥Grade 3 (except alopecia or controlled nausea) or treatment interruption ≥2 weeks due to adverse events.

Time frame:
From first dose (Day 1) and up to 42 days post first dose
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities
Participants1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/1
Number of Participants With Dose Limiting Toxicities0000
PrimaryObjective Response Rate (ORR)

Objective Response Rate (ORR) is the percentage of participants whose best overall response is Complete Response (CR) or Partial Response (PR) per RECIST v1.1. CR is the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. ORR is calculated as: (Number of participants with CR or PR ÷ Total participants) × 100. Confidence intervals are typically estimated using the Clopper-Pearson method.

Time frame:
From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsAll 1A-escalation Participants1B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
Objective Response Rate (ORR)23.1 (5.0 to 53.8)0.0 (0.0 to 100.0)22.2 (11.2 to 37.1)42.6 (29.2 to 56.8)23.1 (13.5 to 35.2)58.7 (43.2 to 73.0)
PrimaryDisease Control Rate (DCR)

Disease Control Rate (DCR) is the percentage of participants whose Best Overall Response (BOR) is Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST v1.1. CR is the disappearance of all target lesions and reduction of any pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum diameters while on study. DCR is calculated as: (Number of participants with CR, PR, or SD ÷ Total participants) × 100.

Time frame:
From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsAll 1A-escalation Participants1B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
Disease Control Rate (DCR)46.2 (19.2 to 74.9)33.3 (4.3 to 77.7)40.0 (25.7 to 55.7)59.3 (45.0 to 72.4)61.5 (48.6 to 73.3)76.1 (61.2 to 87.4)
PrimaryDuration of Response (DoR)

Duration of Response (mDOR) is the median time from the first documented occurrence of Complete Response (CR) or Partial Response (PR) until disease progression or death, assessed per RECIST v1.1. CR is the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. Progression is defined as at least a 20% increase in the sum of diameters of target lesions or appearance of new lesions.

Time frame:
From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Reported as:
Median · months
Duration of Response (DoR)
monthsAll 1A-escalation Participants1B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
Duration of Response (DoR)NA (NA to NA)—18.50 (6.83 to NA)NA (21.09 to NA)21.88 (5.55 to 28.25)NA (NA to NA)
SecondaryProgression Free Survival (PFS)

Progression-Free Survival (PFS) is the time from randomization or treatment start until the first documented disease progression or death from any cause, whichever occurs first, assessed per RECIST v1.1. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions (minimum 5 mm absolute increase) or appearance of new lesions. Participants without progression or death are censored at the date of last adequate tumor assessment. PFS is typically analyzed using Kaplan-Meier estimates and reported in months.

Time frame:
From the date of first dose (Day 1) to up to the date of the first documented disease progression or death (up to approximately 80 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsAll 1A-escalation Participants1B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
Progression Free Survival (PFS)2.30 (1.84 to 36.93)2.45 (1.64 to NA)1.87 (1.74 to 3.58)4.44 (1.87 to 23.06)3.81 (2.53 to 7.10)NA (3.94 to NA)
SecondaryProgression Free Survival Rate at 6 and 12 Months

Progression-Free Survival Rate (PFSR) is the percentage of participants who remain alive without disease progression, assessed per RECIST v1.1. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions (minimum 5 mm absolute increase) or appearance of new lesions. Participants without progression or death by the time point are considered event-free

Time frame:
Month 6 and 12
Reported as:
Number · percentage of participants
Progression Free Survival Rate at 6 and 12 Months
percentage of participantsAll 1A-escalation Participants1B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
6-month30.8 (9.5 to 55.4)33.3 (4.6 to 67.6)26.0 (13.8 to 40.0)46.2 (32.2 to 59.0)40.9 (28.5 to 53.0)62.4 (46.0 to 75.0)
12-month30.8 (9.5 to 55.4)0.0 (NA to NA)17.6 (7.6 to 31.0)40.1 (26.8 to 53.1)26.1 (15.5 to 37.9)62.4 (46.0 to 75.0)

Adverse events

Collected over SAEs and Non-SAEs were collected from first dose (Day 1) and within 100 days of last dose of study therapy (up to approximately 71 months). All cause mortality was collected from first dose and up to approximately 80 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1A-esc-480/160/252/3 (66.7%)1/3 (33.3%)3/3 (100%)
1A-esc-480/160/502/3 (66.7%)1/3 (33.3%)3/3 (100%)
1A-esc-480/160/1005/7 (71.4%)6/7 (85.7%)7/7 (100%)
1B-esc-160/480/13/6 (50%)4/6 (66.7%)6/6 (100%)
2A-SCCHN IO Naive-160/480/10035/45 (77.8%)29/45 (64.4%)36/45 (80%)
2A-MEL 1L-160/480/10021/54 (38.9%)21/54 (38.9%)52/54 (96.3%)
2B-NSCLC 1L-160/480/146/65 (70.8%)38/65 (58.5%)63/65 (96.9%)
2B-MEL 1L-160/480/115/46 (32.6%)27/46 (58.7%)43/46 (93.5%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
Event1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
Acute myocardial infarctionCardiac disorders0/31/30/70/60/450/540/650/46
FallInjury, poisoning and procedural complications1/30/30/70/60/450/540/650/46
Pelvic fractureInjury, poisoning and procedural complications1/30/30/70/60/450/540/650/46
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/32/70/63/452/543/653/46
Adrenal insufficiencyEndocrine disorders0/30/30/71/60/450/541/650/46
HypopituitarismEndocrine disorders0/30/30/71/60/450/540/650/46
Lymphocytic hypophysitisEndocrine disorders0/30/30/71/60/450/540/650/46
OsteoarthritisMusculoskeletal and connective tissue disorders0/30/30/71/60/450/540/650/46
Bronchial obstructionRespiratory, thoracic and mediastinal disorders0/30/30/71/60/450/540/650/46
HaemoptysisRespiratory, thoracic and mediastinal disorders0/30/30/71/60/450/541/650/46
Most frequent other events
Showing 10 of 161
Most frequent other events
Event1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1
RashSkin and subcutaneous tissue disorders0/31/34/71/61/456/5411/6510/46
Alanine aminotransferase increasedInvestigations1/30/31/70/66/4528/5411/658/46
Dry mouthGastrointestinal disorders0/31/30/73/63/453/548/658/46
NauseaGastrointestinal disorders0/30/32/73/62/4517/5414/6511/46
FatigueGeneral disorders0/31/32/73/66/458/5421/6515/46
Aspartate aminotransferase increasedInvestigations1/30/31/70/66/4526/5411/659/46
DiarrhoeaGastrointestinal disorders0/30/31/72/65/458/5423/6519/46
AstheniaGeneral disorders0/30/30/70/617/4511/5426/6513/46
PruritusSkin and subcutaneous tissue disorders1/30/30/71/64/453/5416/6517/46
Angina pectorisCardiac disorders1/30/30/70/60/450/540/650/46

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1Total
<=18 years000000000
Between 18 and 65 years233430383027137
>=65 years10421516351992
Sex: Female, Male
Sex: Female, Male(Participants)1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1Total
Female10431123241278
Male233334314134151
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1Total
Hispanic or Latino000000000
Not Hispanic or Latino337627255320144
Unknown or Not Reported00001829122685
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)1A-esc-480/160/251A-esc-480/160/501A-esc-480/160/1001B-esc-160/480/12A-SCCHN IO Naive-160/480/1002A-MEL 1L-160/480/1002B-NSCLC 1L-160/480/12B-MEL 1L-160/480/1Total
White227536416146200
Black or African American000110002
Asian100010204
Other0100432010
Not reported00003100013
08

Study locations

22 sites
  • Local Institution - 0006
    Duarte, California 91010, United States
  • Local Institution - 0003
    Aurora, Colorado 80045, United States
  • Local Institution - 0004
    Baltimore, Maryland 21231, United States
  • Local Institution - 0005
    St Louis, Missouri 63110, United States
  • Local Institution - 0001
    Germantown, Tennessee 38138, United States
  • Local Institution - 0012
    Wollstonecraft, New South Wales 2065, Australia
  • Local Institution - 0011
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0017
    Marseille, 13385, France
  • Local Institution - 0016
    Toulouse, 31059, France
  • Local Institution - 0015
    Villejuif, 94800, France
  • Local Institution - 0010
    Forlì, 47014, Italy
  • Local Institution - 0009
    Naples, 80131, Italy
  • Local Institution - 0023
    Rome, 00144, Italy
  • Local Institution - 0019
    Barcelona, 08036, Spain
  • Local Institution - 0021
    Madrid, 28041, Spain
  • Local Institution - 0018
    Madrid, 28050, Spain
  • Local Institution - 0022
    Málaga, 29011, Spain
  • Local Institution - 0020
    Pamplona, 31008, Spain
  • Local Institution - 0008
    Lausanne, 1011, Switzerland
  • Local Institution - 0007
    Zurich, 8091, Switzerland
  • Local Institution - 0013
    Headington, OX3 7LE, United Kingdom
  • Local Institution - 0014
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Feb 2025, 80 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Mar 8, 2018
StartActual
May 30, 2018
Primary completionActual
Feb 19, 2025
CompletionActual
Feb 19, 2025
Results first posted
Apr 6, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03459222
Responsible party
Sponsor
First posted
Mar 8, 2018
Start date
May 30, 2018
Primary completion
Feb 19, 2025
Completion
Feb 19, 2025
Results posted
Apr 6, 2026
Last update
Apr 6, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linrodostat

Start the discussion